Skip to content
Canadian Pharmacy Regulatory Authorities:
AB
BC
MB
NB
NL
NS
NT
NU
ON
PE
QC
SK
YT
All
Search for:
Search
Search
National Drug Schedules Program
NDS Database
About the NDS Program
Drug Scheduling in Canada
What Are the NDS?
NDS Policies
NDS Implementation Across Canada
Subscribe to NDS Updates
NDS Submissions
NDS Process
Summary of the NDS Process
Participation in NDS Reviews
NDS Advisory Committee
National Drug Scheduling Advisory Committee (NDSAC)
NDSAC Meetings
Resources
Publications
NAPRA Annual Reports
NAPRA Diagnostic Tool and Learning Modules (DTLM)
National Statistics
Pharmacy Regulatory Authorities
Online Pharmacies
International
News
About NAPRA
National Drug Schedules Program
NDS Database
About the NDS Program
Drug Scheduling in Canada
What Are the NDS?
NDS Policies
NDS Implementation Across Canada
Subscribe to NDS Updates
NDS Submissions
NDS Process
Summary of the NDS Process
Participation in NDS Reviews
NDS Advisory Committee
National Drug Scheduling Advisory Committee (NDSAC)
NDSAC Meetings
Resources
Publications
NAPRA Annual Reports
NAPRA Diagnostic Tool and Learning Modules (DTLM)
National Statistics
Pharmacy Regulatory Authorities
Online Pharmacies
International
News
About NAPRA
Login
NAPRA Groups
Afamelanotide or its salts
Afamelanotide or its salts
Approval Date:
August 27, 2026
Schedule:
I
Footnote:
PDL
